Aldeyra Therapeutics, Inc (NASDAQ:ALDX) CFO Joshua Reed acquired 3,200 shares of the firm’s stock in a transaction on Thursday, September 5th. The stock was bought at an average price of $4.71 per share, with a total value of $15,072.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of ALDX traded down $0.03 on Monday, reaching $4.90. The stock had a trading volume of 120,799 shares, compared to its average volume of 379,118. Aldeyra Therapeutics, Inc has a 12-month low of $4.31 and a 12-month high of $16.70. The firm has a market capitalization of $132.38 million, a price-to-earnings ratio of -2.74 and a beta of 0.61. The company has a 50-day simple moving average of $5.05 and a 200-day simple moving average of $6.88.
Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.51) by $0.02. As a group, sell-side analysts predict that Aldeyra Therapeutics, Inc will post -2.01 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the business. Private Advisors LLC grew its position in shares of Aldeyra Therapeutics by 50.4% in the 1st quarter. Private Advisors LLC now owns 33,151 shares of the biotechnology company’s stock worth $299,000 after buying an additional 11,112 shares during the period. Ironwood Investment Management LLC purchased a new position in Aldeyra Therapeutics during the 1st quarter valued at about $116,000. National Asset Management Inc. boosted its stake in Aldeyra Therapeutics by 69.4% during the first quarter. National Asset Management Inc. now owns 27,006 shares of the biotechnology company’s stock worth $244,000 after acquiring an additional 11,066 shares in the last quarter. Thompson Siegel & Walmsley LLC bought a new stake in Aldeyra Therapeutics during the first quarter worth about $244,000. Finally, Prescott Group Capital Management L.L.C. bought a new stake in Aldeyra Therapeutics during the first quarter worth about $948,000. 61.26% of the stock is owned by institutional investors and hedge funds.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Recommended Story: Why does the United States have a lingering trade deficit?
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.